SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biocryst Pharmaceuticals Initiates a Phase 2b Study of BCX4208 as Add-on Therapy in Gout Patients Not Responding to Allopurinol Alone

December 22, 2010 | 
1 min read
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.
Clinical research Phase II
BioCryst Pharmaceuticals, Inc.
MORE ON THIS TOPIC
halftone magazine style banner, dislike, negative rating, hand thumbs down
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
September 4, 2025
 · 
1 min read
 · 
Lori Ellis
Sea wave. Hand drawn realistic vector illustration in oriental vintage ukiyo-e style.
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac